Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $46.02 million. The enterprise value is $29.97 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 27.72 million shares outstanding. The number of shares has increased by 63.11% in one year.
Current Share Class | 27.72M |
Shares Outstanding | 27.72M |
Shares Change (YoY) | +63.11% |
Shares Change (QoQ) | +0.47% |
Owned by Insiders (%) | 20.99% |
Owned by Institutions (%) | 15.65% |
Float | 17.99M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.53 |
P/TBV Ratio | 3.51 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.08.
Current Ratio | 2.33 |
Quick Ratio | 2.26 |
Debt / Equity | 0.08 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -147.33% and return on invested capital (ROIC) is -92.84%.
Return on Equity (ROE) | -147.33% |
Return on Assets (ROA) | -66.11% |
Return on Invested Capital (ROIC) | -92.84% |
Return on Capital Employed (ROCE) | -159.00% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.27M |
Employee Count | 17 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $41,037 in taxes.
Income Tax | 41,037 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.63% in the last 52 weeks. The beta is 0.25, so Immix Biopharma's price volatility has been lower than the market average.
Beta (5Y) | 0.25 |
52-Week Price Change | -44.63% |
50-Day Moving Average | 1.84 |
200-Day Moving Average | 1.92 |
Relative Strength Index (RSI) | 45.15 |
Average Volume (20 Days) | 46,664 |
Short Selling Information
The latest short interest is 367,356, so 1.33% of the outstanding shares have been sold short.
Short Interest | 367,356 |
Short Previous Month | 386,334 |
Short % of Shares Out | 1.33% |
Short % of Float | 2.04% |
Short Ratio (days to cover) | 6.52 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -22.67M |
Pretax Income | -18.18M |
Net Income | -21.61M |
EBITDA | -22.64M |
EBIT | -22.67M |
Earnings Per Share (EPS) | -$0.76 |
Full Income Statement Balance Sheet
The company has $17.68 million in cash and $1.07 million in debt, giving a net cash position of $16.61 million or $0.60 per share.
Cash & Cash Equivalents | 17.68M |
Total Debt | 1.07M |
Net Cash | 16.61M |
Net Cash Per Share | $0.60 |
Equity (Book Value) | 13.25M |
Book Value Per Share | 0.48 |
Working Capital | 11.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$14.60 million and capital expenditures -$1.18 million, giving a free cash flow of -$15.77 million.
Operating Cash Flow | -14.60M |
Capital Expenditures | -1.18M |
Free Cash Flow | -15.77M |
FCF Per Share | -$0.57 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |